Personalized mRNA vaccine plus standard treatment for advanced digestive cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced (locally advanced or metastatic) digestive system cancer like stomach, colon, pancreatic, or liver cancer.
- You have received at least 4 cycles of standard first-line treatment as per your doctor's advice.
- Your cancer can be measured on scans (CT/MRI) and you have enough tumor tissue available for genetic testing.
- You are in generally good health (ECOG performance status 0-1) with adequate organ function (heart, liver, kidneys, blood counts).
- You agree to use contraception (if applicable) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.
This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hear when a new Digestive System Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.